NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 1 - Gastro-intestinal system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
01.05.03 Drugs affecting the immune response
Bedfordshire & Luton JPC Crohn’s Disease Biologic Treatment Pathway BLMK APC Ulcerative Colitis (Moderate to Severe) Biologic Treatment Pathway
01.05.03 Cytokine inhibitors
Bedfordshire & Luton JPC Crohn’s Disease Biologic Treatment Pathway BLMK APC Ulcerative Colitis (Moderate to Severe) Biologic Treatment Pathway

Adalimumab (Amgevita®)
(Gastroenterology)

RED
Restricted Drug Restricted

Choice:

Amgevita (biosimilar brand) preferred brand for new patients.

Imraldi & Idacio for existing patients only

Humira for existing patients only (originator brand)

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
 
 
Restricted to prescribing by NICE criteria or by approved individual funding request (IFR) ONLY.
 

BNF BNFc SPC
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Golimumab

RED
Restricted Drug Restricted
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted to prescribing by NICE criteria or by approved individual funding request (IFR) ONLY.

50mg Pre-filled Pen
50mg Pre-filled Syringe
BNF BNFc SPC
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Guselkumab (Tremfya®)
(100mg PFP, 200mg PFP, 200mg concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

 

Updated: September 2025

BNF BNFc SPC
NICE TA1094: Guselkumab for treating moderately to severely active ulcerative colitis NICE TA1095: Guselkumab for previously treated moderately to severely active Crohn’s disease

Infliximab (Remsima®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Remicade (originator brand) for existing patients only
 
Restricted to prescribing by NICE criteria or by approved individual funding request (IFR) ONLY.

BNF BNFc SPC BlueTeq
JPC: Infliximab for the management of diarrhoea or colitis associated with Immune Checkpoint Inhibitor (ICPI) therapy NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab NICE TA163: Ulcerative colitis (acute manifestations) Infliximab NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Infliximab solution for injection Pre-filled pen (Remsima®)

RED
Restricted Drug Restricted

Available as an option at standard licensed doses.

BNF BNFc SPC

Mirikizumab (Omvoh ®)
(100mg pre-filled pen; 300 mg concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

BNF BNFc SPC BlueTeq
NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis NICE TA1080: Mirikizumab for treating moderately to severely active Crohn’s disease

Upadacitinib (Rinvoq®)
(15mg, 30mg and 45mg p/r tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

BNF BNFc SPC BlueTeq
MHRA DSU April 2023 - Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease

Risankizumab (Skyrizi®)
(600mg concentrate for solution for infusion, 360mg solution for injection in cartridge)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

To be used in accordance with the following NICE TA(s) only:

BNF BNFc SPC BlueTeq
NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease NICE TA998: Risankizumab for treating moderately to severely active ulcerative colitis
01.05.03 Vedolizumab
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.